DNA, Drugs and Targeted Protein Degradation

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

DNA

Drugs

Targeted Protein Degradation

New platform set to accelerate early-stage targeted protein degradation

Sygnature Discovery

MARCH 7, 2023

Sygnature Discovery, the global integrated drug discovery company, has unveiled a new platform that facilitates the combinational high-throughput assembly and review of molecular degraders ( CHARMED ), in response to a sustained rise in demand for its multi-disciplinary expertise. What is the CHARMED platform?

Targeted Protein Degradation

Targeted Protein Degradation DNA Engineering Drugs

Antibody-drug conjugates payloads: then, now and next

Drug Target Review

OCTOBER 4, 2023

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 1 However, efforts proved less effective than the original drugs, owing mostly to insufficient toxicity against cancer cells.

Small Molecule

Small Molecule Drugs Immune Response Targeted Protein Degradation

Drug Discovery Digest

New platform set to accelerate early-stage targeted protein degradation

Antibody-drug conjugates payloads: then, now and next

Stay Connected